17,261 trials
Acute Myelogenous Leukemia · Acute Lymphoid Leukemia · Juvenile Myelomonocytic Leukemia
Primary: Relapse Rate — 23.5 percentage of participants
Prostate Cancer
Primary: Safety, as Measured by the Number of Patients With at Least One Adverse Event as Assess by NCI Common Terminology Criteria for Adverse Events (CTCAE) vs. 40 When…
Classical Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 87.1 Percentage of Participants — p=<0.0001
Infectious Skin Disease · Bacterial Skin Disease
Primary: Number of Participants With Clinical Response in the Modified Intent-to-Treat (mITT) Population — 75; 59; 9; 19 participants
Urologic Neoplasms
Primary: Number of Participants With Progression-free Survival at Six Months (PFS6) in Cohort A — 4 Participants
Refractory Multiple Myeloma
Primary: Phase I: Highest Tolerated Low Dose (HTLD) — 50; 50 mg/m^2
Diabetes Mellitus, Type 2
Primary: Fasting Serum Glucose — 6.6; 7.3; 8.2 mmol/L — p=0.031
Multiple Sclerosis
Primary: Bioequivalence of 20 mg Ofatumumab Injected by Pre-filled Syringe (PFS) vs Autoinjector (AI) to Abdomen as Measured by AUCtau — 487.7; 474.1 h×µg/mL
Systemic Lupus Erythematosus · Arthritis
Primary: Arthritis Complete Response — 4; 0 participants
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants
Choroidal Neovascularization
Primary: Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants — 7.61; 9.18; 6.02; 6.10 BCVA Letters — p=0.5244
Hepatitis C Virus Infection
Primary: PK Lead-in Phase: AUCtau: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval of Velpatasvir (VEL) — 4479.3; 3697.5; 4450.3 hours*nanograms…
Hypertension, Portal
Primary: Change in Portal Pressure at Year 1 (Change in HVPG From Baseline and 1 Year) — -0.39; -0.24; 0.19 mm HG — p=1.000
Crohn's Disease
Primary: Change in Simple Endoscopic Score for Crohn's Disease (SES-CD) (Paired Segments) From Baseline at Week 12 as Determined by a Blinded Central Reader. — -2.3 Units on a…
Hemophilia A
Primary: Hemophilia Joint Health Score (HJHS) 2.0 — 3.77 score on a scale